Security
Amphastar Pharmaceuticals, Inc. Common Stock · AMPH
AMPHNASDAQCommon stockCurrentCIK 1297184Updated Oct 6, 2026
AMPH price & chart
Loading TradingView…
NASDAQ:AMPH on TradingView ↗About the company
Amphastar is a biopharmaceutical company that focuses on developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells active pharmaceutical ingredient, or API products. Most of the Company’s finished products are contracted and distributed through group purchasing organizations, drug wholesalers, and drug retailers. More information and resources are available at www.amphastar.com.
In the news
Amphastar Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 1,666,222,000Source | 1,545,178,000Source | 1,743,766,000Source | 1,615,333,000Source | 1,491,522,000Source | 1,648,162,000Source | 1,626,276,000Source | 1,574,317,000Source | 1,629,299,000Source | 1,577,470,000Source | 1,512,912,000Source | 741,987,000Source |
| Property, Plant and Equipment, NetUSD | 308,689,000Source | 295,384,000Source | 316,063,000Source | 310,239,000Source | 287,999,000Source | 307,231,000Source | 307,602,000Source | 288,523,000Source | 310,567,000Source | 297,345,000Source | 282,746,000Source | 238,266,000Source |
| GoodwillUSD | 3,404,000Source | 3,256,000Source | 3,311,000Source | 3,397,000Source | 3,129,000Source | 3,330,000Source | 3,157,000Source | 3,152,000Source | 3,402,000Source | 3,049,000Source | 3,216,000Source | 3,126,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 216,265,000Source | 192,116,000Source | 223,614,000Source | 187,689,000Source | 189,619,000Source | 170,939,000Source | 182,782,000Source | 201,148,000Source | 170,177,000Source | 151,609,000Source | 144,296,000Source | 156,098,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 146,808,000Source | 139,635,000Source | 144,857,000Source | 132,982,000Source | 131,412,000Source | 147,848,000Source | 144,636,000Source | 138,114,000Source | 143,560,000Source | 136,289,000Source | 114,943,000Source | 88,804,000Source |
| Inventory, NetUSD | 185,932,000Source | 130,316,000Source | 179,907,000Source | 191,731,000Source | 122,411,000Source | 170,194,000Source | 185,476,000Source | 115,494,000Source | 176,890,000Source | 153,741,000Source | 105,833,000Source | 103,584,000Source |
| Assets, CurrentUSD | 639,470,000Source | 545,949,000Source | 630,951,000Source | 580,830,000Source | 482,645,000Source | 633,683,000Source | 587,961,000Source | 555,078,000Source | 636,016,000Source | 534,071,000Source | 489,600,000Source | 378,319,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 26,021,000Source | 17,723,000Source | 11,001,000Source | 20,328,000Source | 7,945,000Source | 11,650,000Source | 17,773,000Source | 8,696,000Source | 13,152,000Source | 18,214,000Source | 9,057,000Source | 7,563,000Source |
| Operating Lease, Right-of-Use AssetUSD | 44,577,000Source | 31,708,000Source | 72,911,000Source | 44,199,000Source | 32,104,000Source | 71,496,000Source | 45,822,000Source | 31,352,000Source | 42,931,000Source | 46,899,000Source | 32,333,000Source | 25,554,000Source |
| Other Assets, NoncurrentUSD | 29,866,000Source | 23,663,000Source | 33,392,000Source | 28,099,000Source | 24,260,000Source | 33,480,000Source | 22,991,000Source | 23,369,000Source | 31,135,000Source | 25,992,000Source | 25,910,000Source | 20,856,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 889,476,000Source | 817,500,000Source | 975,609,000Source | 857,851,000Source | 778,176,000Source | 874,771,000Source | 874,993,000Source | 901,961,000Source | 840,494,000Source | 845,172,000Source | 873,491,000Source | 213,329,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 6,000Source | 6,000Source |
| Additional Paid in CapitalUSD | 527,215,000Source | 496,427,000Source | 553,002,000Source | 520,581,000Source | 487,571,000Source | 543,816,000Source | 509,108,000Source | 476,072,000Source | 535,380,000Source | 505,400,000Source | 486,056,000Source | 455,077,000Source |
| Retained Earnings (Accumulated Deficit)USD | 642,451,000Source | 530,823,000Source | 703,649,000Source | 625,102,000Source | 490,394,000Source | 673,301,000Source | 594,071,000Source | 452,445,000Source | 666,881,000Source | 568,787,000Source | 409,268,000Source | 271,723,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -5,273,000Source | -8,821,000Source | -5,904,000Source | -5,361,000Source | -8,826,000Source | -5,736,000Source | -7,969,000Source | -8,769,000Source | -5,314,000Source | -9,181,000Source | -8,478,000Source | -8,624,000Source |
| Liabilities and EquityUSD | 1,666,222,000Source | 1,545,178,000Source | 1,743,766,000Source | 1,615,333,000Source | 1,491,522,000Source | 1,648,162,000Source | 1,626,276,000Source | 1,574,317,000Source | 1,629,299,000Source | 1,577,470,000Source | 1,512,912,000Source | 741,987,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 205,227,000Source | 159,010,000Source | 263,205,000Source | 176,407,000Source | 136,971,000Source | 164,478,000Source | 199,052,000Source | 255,169,000Source | 158,156,000Source | 173,759,000Source | 225,407,000Source | 94,862,000Source |
| Operating Lease, Liability, CurrentUSD | 7,827,000Source | 4,209,000Source | 8,800,000Source | 7,879,000Source | 3,996,000Source | 9,705,000Source | 7,746,000Source | 3,942,000Source | 7,928,000Source | 6,804,000Source | 3,906,000Source | 3,003,000Source |
| Accounts Payable, CurrentUSD | 40,540,000Source | 34,088,000Source | 28,928,000Source | 41,881,000Source | 31,775,000Source | 35,500,000Source | 52,813,000Source | 36,534,000Source | 32,592,000Source | 30,514,000Source | 25,438,000Source | 20,501,000Source |
| Operating Lease, Liability, NoncurrentUSD | 39,441,000Source | 28,941,000Source | 67,470,000Source | 38,964,000Source | 29,483,000Source | 65,201,000Source | 40,705,000Source | 28,739,000Source | 37,684,000Source | 41,881,000Source | 29,721,000Source | 23,694,000Source |
| Deferred Income Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | — | — | — | 144,000Source |
| Other Liabilities, NoncurrentUSD | 29,269,000Source | 27,037,000Source | 29,444,000Source | 27,796,000Source | 18,803,000Source | 29,365,000Source | 24,421,000Source | 17,981,000Source | 29,979,000Source | 20,945,000Source | 22,718,000Source | 14,565,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 150,304,000Source | 119,180,000Source | 222,443,000Source | 124,671,000Source | 99,437,000Source | 117,188,000Source | 123,127,000Source | 80,163,000Source | 115,756,000Source | 126,543,000Source | 67,928,000Source | 63,741,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | — | — | — | — | — | — | 619,705,000Source | 613,532,000Source | 603,174,000Source | 76,642,000Source |
| Short-term InvestmentsUSD | 59,944,000Source | 58,375,000Source | 66,509,000Source | 44,062,000Source | 28,156,000Source | 121,012,000Source | 54,101,000Source | 88,407,000Source | 112,635,000Source | 70,036,000Source | 112,510,000Source | 19,664,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | 6,420,000Source | 25,285,000Source | 98,094,000Source | 159,519,000Source | 137,545,000Source | 91,386,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | 14,129,000Source | 13,400,000Source | 14,311,000Source | 14,616,000Source | — | — | — | — | 25,737,000Source | 12,597,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 9,274,000Source | 8,393,000Source | 27,277,000Source | 24,368,000Source | 20,242,000Source | 17,860,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 4,547,000Source | 8,075,000Source | 6,367,000Source | 21,671,000Source | 26,086,000Source | 10,132,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | -6,248,000Source | 31,111,000Source | 21,063,000Source | 48,797,000Source | 1,724,000Source | 11,746,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 28,659,000Source | -17,142,000Source | -13,857,000Source | -15,879,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 47,840,000Source | 35,077,000Source | 156,115,000Source | 213,386,000Source | 183,503,000Source | 89,181,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -16,733,000Source | 10,481,000Source | -70,332,000Source | -124,930,000Source | -649,116,000Source | -32,777,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 9,507,000Source | 10,697,000Source | 34,882,000Source | 41,041,000Source | 38,166,000Source | 24,034,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | 29,492,000Source | 11,000,000Source | 75,586,000Source | 85,458,000Source | 58,144,000Source | 39,909,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -30,207,000Source | -14,503,000Source | -67,425,000Source | -80,953,000Source | 454,093,000Source | -26,439,000Source |
| Repayments of Long-term DebtUSD | — | — | — | — | — | — | 29,000Source | 38,000Source | 223,000Source | 8,263,000Source | 318,658,000Source | 1,781,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 762,000Source | 31,173,000Source | 18,568,000Source | 7,313,000Source | -11,802,000Source | 29,745,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 216,500,000Source | 192,351,000Source | 223,849,000Source | 187,924,000Source | 171,174,000Source | 183,017,000Source | 170,412,000Source | 151,844,000Source | 144,531,000Source | 156,333,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 7,295,000Source | 7,582,000Source | 23,218,000Source | 26,811,000Source | 17,573,000Source | 3,023,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | -4,111,000Source | -902,000Source | 22,710,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -138,000Source | 118,000Source | 210,000Source | -190,000Source | -282,000Source | -220,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 6,297,000Source | 5,596,000Source | 7,090,000Source | 6,382,000Source | 9,274,000Source | 8,393,000Source | 27,277,000Source | 24,368,000Source | 20,242,000Source | 17,860,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | — | — | 3,355,000Source | 6,032,000Source | 11,399,000Source | — |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 6,270,000Source | 6,240,000Source | 25,048,000Source | 24,718,000Source | 12,830,000Source | 1,420,000Source |
| Capitalized Computer Software, AmortizationUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | — | — |
| DepreciationUSD | — | — | — | — | — | — | 8,078,000Source | 7,369,000Source | 31,647,000Source | 28,249,000Source | 25,205,000Source | 23,815,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | -4,000Source | -2,000Source | -39,000Source | -9,000Source | -475,000Source | -141,000Source |
| General and Administrative ExpenseUSD | — | — | 39,467,000Source | 14,821,000Source | 18,242,000Source | 13,991,000Source | 18,028,000Source | 15,996,000Source | 85,925,000Source | 56,720,000Source | 51,540,000Source | 45,061,000Source |
| GoodwillUSD | — | — | 3,404,000Source | 3,256,000Source | 3,311,000Source | 3,397,000Source | 3,330,000Source | 3,157,000Source | 3,402,000Source | 3,049,000Source | 3,216,000Source | 3,126,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | — | — | — | — | — | -573,000Source | -1,981,000Source | -1,177,000Source |
| Income Tax Expense (Benefit)USD | — | — | 4,163,000Source | 7,254,000Source | 8,196,000Source | 8,305,000Source | 3,632,000Source | 5,577,000Source | 25,530,000Source | 29,672,000Source | 31,833,000Source | 23,477,000Source |
| InterestExpenseNonoperatingUSD | — | — | 6,284,000Source | 6,698,000Source | 6,659,000Source | 6,281,000Source | 6,553,000Source | 6,286,000Source | 25,481,000Source | 30,343,000Source | — | — |
| Inventory Write-downUSD | — | — | 1,300,000Source | 900,000Source | 2,700,000Source | 2,700,000Source | 2,200,000Source | 200,000Source | 6,000,000Source | 14,000,000Source | 18,800,000Source | 17,200,000Source |
| Investment Income, InterestUSD | — | — | 2,246,000Source | 2,427,000Source | 2,287,000Source | 1,921,000Source | 2,400,000Source | 2,089,000Source | 8,679,000Source | 10,612,000Source | 5,459,000Source | 1,321,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 17,350,000Source | 40,429,000Source | 30,348,000Source | 31,030,000Source | 6,420,000Source | 25,285,000Source | 98,094,000Source | 159,519,000Source | 137,545,000Source | 91,386,000Source |
| Nonoperating Income (Expense)USD | — | — | -3,807,000Source | -9,365,000Source | -1,185,000Source | -2,849,000Source | -3,578,000Source | -6,431,000Source | -16,779,000Source | -15,655,000Source | -25,628,000Source | 8,543,000Source |
| Operating ExpensesUSD | — | — | 73,326,000Source | 44,893,000Source | 53,741,000Source | 44,306,000Source | 56,692,000Source | 47,958,000Source | 215,654,000Source | 168,436,000Source | 154,134,000Source | 141,363,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 231,000Source | -5,094,000Source | 3,187,000Source | 1,511,000Source | 575,000Source | -2,234,000Source | 23,000Source | 4,076,000Source | -3,929,000Source | 9,068,000Source |
| Pension Cost (Reversal of Cost)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | — |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | — | — | — | — | 845,000,000Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | 411,000Source | 3,332,000Source | 312,000Source | 3,318,000Source | 1,850,000Source | 2,068,000Source | 6,388,000Source | 12,239,000Source | 14,172,000Source | 19,202,000Source |
| Amortization of Debt Issuance Costs and Discounts | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Operating Lease, Expense | — | — | —Source | — | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 191,840,000Source | 191,214,000Source | 183,903,000Source | 174,414,000Source | 171,171,000Source | 170,528,000Source | 719,887,000Source | 731,967,000Source | 644,395,000Source | 498,987,000Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Operating Income (Loss)USD | — | — | 25,320,000Source | 57,048,000Source | 39,729,000Source | 42,184,000Source | 13,630,000Source | 37,293,000Source | 140,403,000Source | 205,419,000Source | 196,987,000Source | 107,497,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 231,000Source | -5,094,000Source | 3,187,000Source | 1,511,000Source | 575,000Source | -2,234,000Source | 23,000Source | 4,076,000Source | -3,929,000Source | 9,068,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 21,513,000Source | 47,683,000Source | 38,544,000Source | 39,335,000Source | 10,052,000Source | 30,862,000Source | 123,624,000Source | 189,764,000Source | 171,359,000Source | 116,040,000Source |
| Income Tax Expense (Benefit)USD | — | — | 4,163,000Source | 7,254,000Source | 8,196,000Source | 8,305,000Source | 3,632,000Source | 5,577,000Source | 25,530,000Source | 29,672,000Source | 31,833,000Source | 23,477,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 17,350,000Source | 40,429,000Source | 30,348,000Source | 31,030,000Source | 6,420,000Source | 25,285,000Source | 98,094,000Source | 159,519,000Source | 137,545,000Source | 91,386,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 0.38Source | 0.83Source | 0.69Source | 0.66Source | 0.14Source | 0.53Source | 2.1Source | 3.29Source | 2.85Source | 1.88Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0.37Source | 0.78Source | 0.67Source | 0.64Source | 0.14Source | 0.51Source | 2.03Source | 3.06Source | 2.6Source | 1.74Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 46,474,000Source | 48,621,000Source | 43,644,000Source | 46,949,000Source | 45,322,000Source | 47,641,000Source | 46,743,000Source | 48,429,000Source | 48,265,000Source | 48,551,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 47,677,000Source | 51,862,000Source | 44,225,000Source | 48,128,000Source | 46,458,000Source | 49,890,000Source | 48,215,000Source | 52,058,000Source | 53,001,000Source | 52,427,000Source |
| Interest Expense (non-operating)USD | — | — | 6,284,000Source | 6,698,000Source | 6,659,000Source | 6,281,000Source | 6,553,000Source | 6,286,000Source | 25,481,000Source | 30,343,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | 6,270,000Source | 6,240,000Source | 25,048,000Source | 24,718,000Source | 12,830,000Source | 1,420,000Source |
| Capitalized Computer Software, AmortizationUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | — | — | — |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -3,129,000Source | 46,814,000Source | 45,690,000Source | 39,356,000Source |
| General and Administrative ExpenseUSD | — | — | 39,467,000Source | 14,821,000Source | 18,242,000Source | 13,991,000Source | 18,028,000Source | 15,996,000Source | 85,925,000Source | 56,720,000Source | 51,540,000Source | 45,061,000Source |
| Gross ProfitUSD | — | — | 98,646,000Source | 101,941,000Source | 93,470,000Source | 86,490,000Source | 70,322,000Source | 85,251,000Source | 356,057,000Source | 373,855,000Source | 351,121,000Source | 248,860,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 128,952,000Source | 195,178,000Source | 181,922,000Source | 127,204,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | — | — | — | — | — | — | -573,000Source | -1,981,000Source | -1,177,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 27,158,000Source | 1,846,000Source |
| Investment Income, InterestUSD | — | — | 2,246,000Source | 2,427,000Source | 2,287,000Source | 1,921,000Source | 2,400,000Source | 2,089,000Source | 8,679,000Source | 10,612,000Source | 5,459,000Source | 1,321,000Source |
| Nonoperating Income (Expense)USD | — | — | -3,807,000Source | -9,365,000Source | -1,185,000Source | -2,849,000Source | -3,578,000Source | -6,431,000Source | -16,779,000Source | -15,655,000Source | -25,628,000Source | 8,543,000Source |
| Operating ExpensesUSD | — | — | 73,326,000Source | 44,893,000Source | 53,741,000Source | 44,306,000Source | 56,692,000Source | 47,958,000Source | 215,654,000Source | 168,436,000Source | 154,134,000Source | 141,363,000Source |
| Research and Development ExpenseUSD | — | — | 22,354,000Source | 21,077,000Source | 22,164,000Source | 20,080,000Source | 26,737,000Source | 20,096,000Source | 85,844,000Source | 73,914,000Source | 73,741,000Source | 74,771,000Source |
| Selling and Marketing ExpenseUSD | — | — | 11,505,000Source | 8,995,000Source | 13,335,000Source | 10,235,000Source | 11,927,000Source | 11,866,000Source | 43,885,000Source | 37,802,000Source | 28,853,000Source | 21,531,000Source |
| Labor and Related Expense | — | — | —Source | —Source | —Source | —Source | — | — | — | — | — | — |
| Marketing and Advertising Expense | — | — | —Source | —Source | —Source | —Source | — | — | — | — | — | — |
| Operating Lease, Expense | — | — | —Source | — | — | — | — | — | — | — | — | — |
Filing attachments
amph-20260806xex99d1.htm · 8-K · 2026-08-06
EX-99.1 2 amph-20260806xex99d1.htm EX-99.1 EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026 Net revenues of $183.9 million for the three months ended June 30, 2026 GAAP net income of $30.3 million, or $0.67 per share, for the second quarter Adjusted non-GAAP net income of $40.8 million, or $0.91 per share, for the second quarter Company to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, CA - Augus…
Read attachment ↗amph-20260507xex99d1.htm · 8-K · 2026-05-07
EX-99.1 2 amph-20260507xex99d1.htm EX-99.1 EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 Net revenues of $171.2 million for the three months ended March 31, 2026 GAAP net income of $6.4 million, or $0.14 per share, for the first quarter Adjusted non-GAAP net income of $19.5 million, or $0.42 per share, for the first quarter Company to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, CA - May 7,…
Read attachment ↗amph-20260226xex99d1.htm · 8-K · 2026-02-26
EX-99.1 2 amph-20260226xex99d1.htm EX-99.1 EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025 Net revenues of $183.1 million and $719.9 million, respectively, for the three months and fiscal year ended December 31, 2025 GAAP net income of $24.4 million, or $0.51 per share and $98.1 million, or $2.03 per share, respectively, for the fourth quarter and fiscal year Adjusted non-GAAP net income of $34.2 million, o…
Read attachment ↗amph-20260106xex99d1.htm · 8-K · 2026-01-12
EX-99.1 2 amph-20260106xex99d1.htm EX-99.1 Exhibit 99.1 Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound Agreement expands Amphastar’s proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA / ACCESS Newswire / January, 12, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) today announced that it has entered into an exclusive l…
Read attachment ↗amph-20251106xex99d1.htm · 8-K · 2025-11-06
EX-99.1 2 amph-20251106xex99d1.htm EX-99.1 EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2025 Reports Net Revenues of $191.8 million for the Three Months Ended September 30, 2025 GAAP net income of $17.4 million, or $0.37 per share, for the third quarter Adjusted non-GAAP net income of $44.7 million, or $0.93 per share, for the third quarter Company to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAM…
Read attachment ↗amph-20250808xex99d1.htm · 8-K · 2025-08-12
EX-99.1 2 amph-20250808xex99d1.htm EX-99.1 Exhibit 99.1 Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd. Agreement strengthens proprietary peptide pipeline targeting high-value oncology and ophthalmology indications RANCHO CUCAMONGA, CA - August 12, 2025 - Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar”), a biopharmaceutical company focused on developing, manufacturing, and marketing complex…
Read attachment ↗